[go: up one dir, main page]

IL145891A0 - Methods and compositions for modulating an immune response - Google Patents

Methods and compositions for modulating an immune response

Info

Publication number
IL145891A0
IL145891A0 IL14589100A IL14589100A IL145891A0 IL 145891 A0 IL145891 A0 IL 145891A0 IL 14589100 A IL14589100 A IL 14589100A IL 14589100 A IL14589100 A IL 14589100A IL 145891 A0 IL145891 A0 IL 145891A0
Authority
IL
Israel
Prior art keywords
modulating
compositions
methods
immune response
immune
Prior art date
Application number
IL14589100A
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of IL145891A0 publication Critical patent/IL145891A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
IL14589100A 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response IL145891A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12977299P 1999-04-15 1999-04-15
PCT/US2000/010340 WO2000063241A2 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response

Publications (1)

Publication Number Publication Date
IL145891A0 true IL145891A0 (en) 2002-07-25

Family

ID=22441531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14589100A IL145891A0 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response

Country Status (8)

Country Link
EP (1) EP1175223A2 (en)
JP (1) JP2003517284A (en)
AU (1) AU773350B2 (en)
BR (1) BR0009791A (en)
CA (1) CA2370129A1 (en)
IL (1) IL145891A0 (en)
MX (1) MXPA01010332A (en)
WO (1) WO2000063241A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
JP2002221520A (en) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd Predicting immune type
JP2004532633A (en) * 2001-05-09 2004-10-28 ビオ・ビジョン・アーゲー Method for detecting progressive chronic dementia disease, peptide and detection reagent suitable therefor
HRP20030840A2 (en) * 2001-05-17 2005-08-31 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases
GB0116185D0 (en) * 2001-07-02 2001-08-22 Imp College Innovations Ltd Substances
CN100352844C (en) 2001-09-25 2007-12-05 财团法人化学及血清疗法研究所 Recombinant anti-osteopontin antibody and use thereof
CN1662249A (en) * 2002-06-25 2005-08-31 安万特药物公司 Osteopontin, oligodendrocytes and myelination
AU2003258127A1 (en) 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JPWO2004103403A1 (en) * 2003-05-23 2006-07-20 株式会社 免疫生物研究所 Immunocompetent cell activation inhibitors and uses thereof
WO2005100562A1 (en) * 2004-04-12 2005-10-27 Gene Techno Science Co., Ltd. OSTEOPONTIN siRNA
WO2008050907A1 (en) * 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
CN101293916A (en) * 2007-04-24 2008-10-29 上海国健生物技术研究院 Monoclone antibody with combined function epiposition, specificity of osteopontin and uses thereof
KR101746861B1 (en) 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
WO2009147742A1 (en) * 2008-06-06 2009-12-10 株式会社ジーンテクノサイエンス Sirna of human osteopontin
US8617829B2 (en) 2009-09-24 2013-12-31 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
BR112014013565A2 (en) * 2011-12-07 2019-09-24 Arla Foods Amba opn variant for use in cancer treatment or prevention involving at least one cancerous tumor, cancer treatment or prevention method, pharmaceutical composition and nutritional supplement
BR112016000067B1 (en) * 2013-07-05 2022-08-30 Arla Foods Amba USE OF A BOVINE MILK OSTEOPONTINA AND USE OF A VACCINE SYSTEM
US10512673B2 (en) 2015-01-07 2019-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease
CA3095082A1 (en) 2018-04-25 2019-10-31 Health And Happiness (H&H) Hong Kong Limited Combinations of osteopontin and 2'-fucosyllactose for use as medicaments
WO2022226049A1 (en) * 2021-04-20 2022-10-27 University Of Cincinnati A vaccine adjuvant for infectious diseases
CN115707772B (en) * 2021-08-18 2025-08-08 澳门大学 Inducer, macrophage and use thereof
CN120682308B (en) * 2025-06-23 2025-12-02 北京昌盛鸿途生物科技有限公司 Bovine bone marrow peptides and their application in enhancing immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin

Also Published As

Publication number Publication date
JP2003517284A (en) 2003-05-27
BR0009791A (en) 2002-01-08
MXPA01010332A (en) 2002-09-18
AU773350B2 (en) 2004-05-20
WO2000063241A2 (en) 2000-10-26
WO2000063241A9 (en) 2002-03-28
WO2000063241A3 (en) 2001-05-10
EP1175223A2 (en) 2002-01-30
AU4357500A (en) 2000-11-02
CA2370129A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
IL145891A0 (en) Methods and compositions for modulating an immune response
EP1176948A4 (en) Anti-nausea compositions and methods
AUPQ419099A0 (en) Novel compositions and methods
EP1030654A4 (en) Omeprazole formulation
EP1056456A4 (en) R-lansoprazole compositions and methods
IL138207A0 (en) Methods and devices for modulating the immune response
IL143423A0 (en) Insecticidal compositions and insecticidal methods
AU7968398A (en) Compositions, devices, kit and method for modulating immune response
AU2002309486A8 (en) Methods and compositions for modulating the immune system of animals
EP1056457A4 (en) S-lansoprazole compositions and methods
AU7474100A (en) Methods and compositions for reducing immune response
PL343432A1 (en) Methods and devices for modulating the immune response
EP1073333A4 (en) S-rabeprazole compositions and methods
AU2273397A (en) Methods and compositions for modulating an immune response
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
GB9922135D0 (en) Compositions and uses
GB0318107D0 (en) ›-Secretase enzyme compositions and methods
IL140574A0 (en) Methods and compositions for modulating spermatogenesis
AU2002248646A1 (en) Compositions and methods for modulating an immune response
AU4866201A (en) Compositions and methods for use in modulating immune system function
AU8513698A (en) Methods and compositions for designing vaccines
AU8408798A (en) Methods and compositions for inhibiting the proinflammatory response
EP1073332A4 (en) R-rabeprazole compositions and methods
GB9807062D0 (en) Immune response
IL148351A0 (en) Therapeutic immune condition compositions and methods